Prognostic value of the SEER-Medicare myelodysplastic syndromes risk score for a contemporary cohort of patients with MDS.

Authors

null

Amber Afzal

Washington Univ School of Medcn, St. Louis, MO

Amber Afzal , Mark A. Fiala , Meagan Jacoby , Matthew Walter

Organizations

Washington Univ School of Medcn, St. Louis, MO, Washington University School of Medicine in St. Louis, St. Louis, MO, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, Washington University in St. Louis, St. Louis, MO

Research Funding

No funding received

Background: Prognostication of patients with myelodysplastic syndromes (MDS) using IPSS-R is not possible in administrative database analysis. In 2014, a claims-based prognostic scoring system, the SEER-Medicare MDS Risk Score (SMMRS) was developed to risk-stratify MDS patients for overall survival using ICD9 codes {Uno, 2014}. In 2015, ICD9 codes were replaced by ICD10 codes. In this study, we updated SMMRS with inclusion of both ICD-9 and -10 codes, and studied its predictive value for overall survival, leukemia-free survival and initiation of treatment among MDS patients. Methods: Patients with MDS were identified through ICD-O-03 codes in the SEER-Medicare database between 2007 and 2017. SMMRS was calculated using MDS subtype, age, comorbidities, cytopenias, transfusion-dependence, and recent hospital admissions. We analyzed the association of SMMRS with overall survival, leukemia-free survival (time from MDS diagnosis to leukemia), and initiation of treatment (hypomethylating agents /stem cell transplant) in Cox proportional hazards models while adjusting for potential confounders. Results: Patients with MDS (N = 12,710) had a median age of 80 years, half were males, and most were Caucasians. SMMRS stratified patients into low-risk (n = 3155), intermediate-1 risk (n = 3255), intermediate-2 risk (n = 3121), and-high risk (n = 3209) categories at diagnosis. The overall survival, leukemia-free survival and treatment initiation for patients in each SMMRS category is summarized in Table. The 5-year overall survival for the entire cohort was 20%. At 5 years, 10% of the MDS patients had transformed to leukemia, and 1/3rd had started MDS treatment. Conclusions: SMMRS based on ICD-9 and -10 codes predicts overall survival, leukemia-free survival and MDS treatment initiation by stratifying MDS patients into 4 risk-categories. It can be utilized to design/analyze future observational studies.

Time since MDS diagnosis (ΔT).

Overall survival according to SMMRS category (Proportion)
Low-risk
Intermediate-1 risk
Intermediate-2 risk
High-risk
3 years
0.67
0.40
0.18
0.06
5 years
0.50
0.23
0.09
0.02
Adjusted Hazards Ratio (of death)#
reference
1.91

(1.80-2.04)
3.34

(3.14-3.55)
5.50

(5.16-5.86)

Incidence of leukemia according to SMMRS category (Proportion)
Low-risk
Intermediate-1 risk
Intermediate-2 risk
High-risk
3 years
0.05
0.06
0.10
0.15
5 years
0.07
0.08
0.13
*
Adjusted Hazards Ratio#
reference
1.25

(0.99-1.56)
2.00

(1.59-2.51)
2.93

(2.31-3.72)

Treatment initiation according to SMMRS category (Proportion)
Low-risk
Intermediate-1 risk
Intermediate-2 risk
High-risk
3 years
0.25
0.30
0.33
0.40
5 years
0.30
0.33
0.35
*
Adjusted Hazards Ratiõ
reference
1.28

(1.15-1.41)
1.59

(1.43-1.76)
2.34

(2.11-2.59)

* Unable to estimate as few patients were alive at this time-point # Adjusted for Gender, Race, Ethnicity, MDS treatment ̃ Adjusted for Gender, Race, Ethnicity

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e18762)

DOI

10.1200/JCO.2022.40.16_suppl.e18762

Abstract #

e18762

Abstract Disclosures

Similar Abstracts

First Author: Victoria Vardell

Abstract

2023 ASCO Annual Meeting

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases.

First Author: Javier Munoz

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Differential burdens: A study of gastric cancer hospitalization and outcomes across race and ethnicities.

First Author: Chun-Wei Pan

First Author: Kekoa A. Taparra